恩格列净治疗射血分数保留的心力衰竭:伴与不伴糖尿病患者
本研究为EMPEROR-Preserved试验的预设分析,纳入5988例射血分数>40%的心力衰竭患者,比较恩格列净10mg与安慰剂在伴或不伴糖尿病者中的疗效。结果显示恩格列净降低主要终点风险与糖尿病状态无关(HR 0.79 vs 0.78,Pinteraction=0.92),且不增加低血糖风险。
要点
- 恩格列净降低主要终点风险与基线糖尿病状态无关。
- 恩格列净减少心衰总住院也一致,且不增加低血糖风险。
- 恩格列净延缓eGFR下降在糖尿病患者中更明显。
核心结论
- 在射血分数保留的心力衰竭患者中,恩格列净显著降低心衰结局风险,且与基线糖尿病状态无关。
研究设计与样本
- EMPEROR-Preserved试验的预设分析,纳入5988例心功能II-IV级且左室射血分数>40%的心衰患者,随机接受恩格列净10mg或安慰剂。
主要发现
- 伴糖尿病者2938例(49%),其主要结局、心衰总住院和eGFR下降风险更高。
- 恩格列净降低主要终点风险:伴糖尿病HR 0.79(95%CI 0.67-0.94),不伴糖尿病HR 0.78(95%CI 0.64-0.95),Pinteraction=0.92。
- 恩格列净减少心衰总住院的效果在伴与不伴糖尿病者中一致。
- 恩格列净延缓eGFR下降在伴与不伴糖尿病者中均存在,但伴糖尿病者更明显(1.77 vs 0.98 mL/min/1.73m2,Pinteraction=0.01)。
- 基线HbA1c作为连续变量不影响主要结局(Pinteraction=0.26),且两个亚组均未增加低血糖事件风险。
临床怎么用
- 对于射血分数保留的心衰患者,无论是否合并糖尿病,均可考虑使用恩格列净以降低心衰住院和心血管死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Empagliflozin improves outcomes in patients with heart failure with a preserved ejection fraction, but whether the effects are consistent in patients with and without diabetes remains to be elucidated. METHODS: Patients with class II through IV heart failure and a left ventricular ejection fraction >40% were randomized to receive empagliflozin 10 mg or placebo in addition to usual therapy. We undertook a prespecified analysis comparing the effects of empagliflozin versus placebo in patients with and without diabetes. RESULTS: Of the 5988 patients enrolled, 2938 (49%) had diabetes. The risk of the primary outcome (first hospitalization for heart failure or cardiovascular death), total hospitalizations for heart failure, and estimated glomerular filtration rate decline was higher in patients with diabetes. Empagliflozin reduced the rate of the primary outcome irrespective of diabetes status (hazard ratio, 0.79 [95% CI, 0.67, 0.94] for patients with diabetes versus hazard ratio, 0.78 [95% CI, 0.64, 0.95] in patients without diabetes; Pinteraction=0.92). The effect of empagliflozin to reduce total hospitalizations for heart failure was also consistent in patients with and without diabetes. The effect of empagliflozin to attenuate estimated glomerular filtration rate decline during double-blind treatment was also present in patients with and without diabetes, although more pronounced in patients with diabetes (1.77 in diabetes versus 0.98 mL/min/1.73m2 in patients without diabetes; Pinteraction=0.01). Across these 3 end points, the effect of empagliflozin did not differ in patients with prediabetes or normoglycemia (33% and 18% of the patient population, respectively). When investigated as a continuous variable, baseline hemoglobin A1c did not modify the effects on the primary outcome (Pinteraction=0.26). There was no increased risk of hypoglycemic events in either subgroup as compared with placebo. CONCLUSIONS: In patients with heart failure and a preserved ejection fraction enrolled in the EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction), empagliflozin significantly reduced the risk of heart failure outcomes irrespective of diabetes status at baseline. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT03057951.
引用
- Filippatos, Butler, Farmakis, et al. Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes. Circulation. 2022. PMID: 35762322. doi:10.1161/CIRCULATIONAHA.122.059785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。